Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) shares saw an uptick in trading volume on Monday . 9,733,278 shares traded hands during trading, an increase of 2,600% from the previous session’s volume of 360,439 shares.The stock last traded at $1.50 and had previously closed at $1.28.
A number of research firms recently commented on OHRP. Zacks Investment Research lowered shares of Ohr Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 11th. ValuEngine upgraded shares of Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday. HC Wainwright set a $10.00 price objective on shares of Ohr Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 16th. Finally, Roth Capital began coverage on shares of Ohr Pharmaceuticals in a research note on Monday, November 27th. They set a “buy” rating and a $7.00 price objective on the stock.
A number of institutional investors have recently bought and sold shares of the business. Garrison Bradford & Associates Inc. grew its position in Ohr Pharmaceuticals by 482.4% in the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock worth $358,000 after buying an additional 412,000 shares during the last quarter. Wedbush Securities Inc. acquired a new position in Ohr Pharmaceuticals in the 3rd quarter worth approximately $311,000. Vanguard Group Inc. boosted its stake in Ohr Pharmaceuticals by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after purchasing an additional 5,481 shares during the period. Cannell Peter B & Co. Inc. acquired a new position in Ohr Pharmaceuticals in the 2nd quarter worth approximately $187,000. Finally, Renaissance Technologies LLC boosted its stake in Ohr Pharmaceuticals by 242.3% in the 1st quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 162,600 shares during the period. Hedge funds and other institutional investors own 8.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Ohr Pharmaceuticals (OHRP) Sees Strong Trading Volume” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/04/ohr-pharmaceuticals-ohrp-sees-strong-trading-volume.html.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
What are top analysts saying about Ohr Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ohr Pharmaceuticals Inc. and related companies.